Explore how biosimilars are lowering cancer drug costs and reshaping treatment access for patients, providers, and healthcare systems worldwide.

Even if regulatory requirements for biosimilar approval becomes more streamlined, and even if awareness and understanding of biosimilars is improved, they’re still transacting in a market ill ...

"Learn about the differences between biosimilar and generic drugs, their safety and effectiveness, and the barriers to their usage in the healthcare marketplace ...

The U.S. health-care system is at a crossroads. Generic drugs and biosimilars have the potential to reduce costs and improve access to life-saving treatments, but outdated policies and entrenched ...

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what ...

Since their introduction, biosimilars (almost identical copies of an original biologic product) brought with them potential cost savings for patients and healthcare systems.

The launch of eight adalimumab biosimilars so far this year ended Humira's 20-year monopoly, but it's not clear yet if these discounted drugs will save patients money.

How the biosimilar market really works For specialty drugs, the impact of new competitors on costs can be complicated.

A new report from AHIP indicates that biosimilars have the potential to garner savings of $180 billion over 5 years, but there needs to be a review of the approval process for interchangeability ...

Biosimilars have shown to be just as effective as original brand name medications in treating rheumatoid arthritis, and the former may be more cost-effective for patients.

Introduction of biosimilars for the rheumatology drug adalimumab, whose original branded version Humira has long been a blockbuster, appears to have led to a dramatic drop in net spending for ...

Biologic drugs account for a disproportionate share of the increase in pharmaceutical spending in the US and worldwide. Against this backdrop, many look to the expanding market for biosimilars ...